Cargando…
Heterometallic titanium–gold complexes inhibit renal cancer cells in vitro and in vivo
Following recent work on heterometallic titanocene–gold complexes as potential chemotherapeutics for renal cancer, we report here on the synthesis, characterization and stability studies of new titanocene complexes containing a methyl group and a carboxylate ligand (mba = S–C(6)H(4)–COO(–)) bound to...
Autores principales: | Fernández-Gallardo, Jacob, Elie, Benelita T., Sadhukha, Tanmoy, Prabha, Swayam, Sanaú, Mercedes, Rotenberg, Susan A., Ramos, Joe W., Contel, María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal Society of Chemistry
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869729/ https://www.ncbi.nlm.nih.gov/pubmed/27213034 http://dx.doi.org/10.1039/c5sc01753j |
Ejemplares similares
-
In Vitro and in Vivo Evaluation
of Water-Soluble Iminophosphorane Ruthenium(II) Compounds. A Potential
Chemotherapeutic Agent for Triple Negative Breast Cancer
por: Frik, Malgorzata, et al.
Publicado: (2014) -
Organometallic Titanocene–Gold Compounds as
Potential Chemotherapeutics in Renal Cancer. Study of their Protein
Kinase Inhibitory Properties
por: Fernández-Gallardo, Jacob, et al.
Publicado: (2014) -
Titanocene–Gold Complexes Containing N-Heterocyclic
Carbene Ligands Inhibit Growth of Prostate, Renal, and Colon Cancers
in Vitro
por: Mui, Yiu Fung, et al.
Publicado: (2016) -
Preclinical evaluation of an unconventional ruthenium‐gold‐based chemotherapeutic: RANCE‐1, in clear cell renal cell carcinoma
por: Elie, Benelita T., et al.
Publicado: (2019) -
Chemical complexity for targeted function in heterometallic titanium–organic frameworks
por: Castells-Gil, Javier, et al.
Publicado: (2023)